Skip to main content
SpringerLink
Log in

Clinical Aspects of Matrix Metalloproteinases

  • Chapter
Book cover Proteases and Their Inhibitors in Cancer Metastasis

Part of the book series: Cancer Metastasis — Biology and Treatment ((CMBT,volume 4))

  • 106 Accesses

Abstract

Tumor metastasis is ultimately responsible for most cancer deaths. Tumor invasion and metastasis represent a multistep process including basement membrane disruption, stromal infiltration, angiogenesis, intravasation and extravasation and invasion of target organs by tumor cells. All these events require degradation and remodeling of the extracellular matrix (ECM) by various proteolytic enzymes. Among these enzymes, matrix metalloproteinases (MMPs) play a key role at various levels. These enzymes are associated with degradation of a broad spectrum of ECM components. MMPs are also implicated in the remodeling the ECM by creating and maintaining a microenvironment that facilitates angiogenesis and growth of tumors. Thus, in the last years, the exploration of MMPs expression has led to a large bunch of studies on their biological activities and their clinical implications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ahmad A, Hanby A, Dublin E, Poulson R, Smith P, Barnes R, Anglard P, Hart I. Stromelysin 3: an independent prognostic factor for relapse-free survival in breast cancer represents a tumor-induced host response. Am J Pathol 1998; 152: 721–728.

    CAS  PubMed  Google Scholar 

  • Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J. Serum metalloproteinases and their inhibitor. Markers for malignant potential. Br J Cancer 1994; 70: 506–512.

    Article  CAS  PubMed  Google Scholar 

  • Barsky SH, Togo S, Garbisa S, Liotta LA. Type IV collagenase immunoreactivity in invasive breast carcinoma. Lancet 1983; 1: 296–297.

    Article  CAS  PubMed  Google Scholar 

  • Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podahjcer OL, Chenard MP, Rio MC, Chambon P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699–704.

    Article  CAS  ADS  PubMed  Google Scholar 

  • Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam J.P, Kudlow JE, Lippman ME, Salomon DS. Expression of transforming growth factor-α and its messenger ribonucleic acid in human breast cancer: its regulation by oestrogen and its possible functional significance. Mol Endocrinol 1988; 2: 543–555.

    Article  CAS  PubMed  Google Scholar 

  • Bertaux B, Hornebeck W, Eisen AZ, Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 1991; 97: 679–685.

    Article  CAS  PubMed  Google Scholar 

  • Biswas C, Zhang Y, Decastro R, Guo H, Nakamura T, Kataoka H. The human tumor cell-derived stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 434–439.

    CAS  PubMed  Google Scholar 

  • Brassart B, Randoux A, Hornebeck W, Emonard H. Regulation of matrix metalloproteinase-2 (gelatinase A, MMP-2), membrane-type matrix metalloproteinase-1 (MT1-MMP) and tissue inhibitor of metalloproteinases-2 (TIMP-2) expression by elastin-derived peptides in human HT-1080 fibrosarcoma cell line. Clin Exp Metastasis 1998; 16: 489–500.

    Article  CAS  PubMed  Google Scholar 

  • Brooks PC, Stomblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha V beta 3. Cell 1996; 85: 683–693.

    Article  CAS  PubMed  Google Scholar 

  • Brown PD, Bloxidge RE, Anderson E, Howell A. Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metast 1993; 11: 183–189.

    Article  CAS  Google Scholar 

  • Buisson AC, Gilles C, Polette M, Zahm JM, Birembaut P, Tournier JM. Wound repair induced expression of stromelysins is associated to the acquisition of a mesenchymal phenotype in human respiratory epithelial cells. Lab Invest 1996; 74: 658–669.

    CAS  PubMed  Google Scholar 

  • Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S, Birembaut P. Expression of the Extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem 1999; 47: 1575–1580.

    CAS  PubMed  Google Scholar 

  • Chenard MP, O’Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq JP, Duffy MJ. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996; 69: 448–451.

    Article  CAS  PubMed  Google Scholar 

  • Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Activity of type IV collagenases in benign and malignant breast diseases. Br J Cancer 1993; 67: 126–131.

    Article  Google Scholar 

  • Emmert-Buck MR, Emonard HP, Corcoran M, Krutzsch HC, Foidart JM, Stetler-Stevenson WG. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett 1995; 364: 28–32.

    Article  CAS  PubMed  Google Scholar 

  • Emonard H, Remacle A, Noöl A, Grimaud JA, Stetler-Stevenson WG, Foidart JM. Tumor cell surface associated binding site for the Mr 72,000 type IV collagenase. Cancer Res 1992; 52: 845–848.

    Google Scholar 

  • Galateau-Salle F, Luna RE, Horiba K, Sheppard MN, Hayashi T, Fleming MV, Colby TV, Bennett W, Harris CC, Stetler-Stevenson WG, Liotta L, Ferrans VJ, Travis WD. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol 2000; 31: 296–305.

    Article  CAS  PubMed  Google Scholar 

  • Gilles C, Thompson EW. The epithelial to mesenchymal transition and metastatic progresion in carcinoma. Breast J 1996; 2: 83–96.

    Article  Google Scholar 

  • Gilles C, Polette M, Seiki M, Birembaut P, Thompson EW. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest 1997; 76: 651–660.

    CAS  PubMed  Google Scholar 

  • Gohji K, Fujimoto N, Fuji A, Komiyama T, Okawa J, Nakajima M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinase-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res 1996; 56: 3196–9198.

    CAS  PubMed  Google Scholar 

  • Gohji K, Fujimoto N, Hara I, Fujii A, Gotoh A, Okada H, Arakawa S, Kitazawa S, Miyake H, Kamidono S, Nakajima M. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998; 79: 96–101.

    Article  CAS  PubMed  Google Scholar 

  • Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111–122.

    CAS  PubMed  Google Scholar 

  • Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, Pontes JE, Crissman JC, Fridman R. High levels of tissue inhibitor of metalloproteinases-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56: 1654–1659.

    CAS  PubMed  Google Scholar 

  • Guo H, Li R, Zucker S, Toole BP. EMMPRIN (CD147), an inducer of Matrix Metalloproteinase synthesis, also binds to interstitial collagenase to the tumor cell surface. Cancer Res 2000; 60: 888–891.

    CAS  PubMed  Google Scholar 

  • Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metallopro-teinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 273–282.

    CAS  PubMed  Google Scholar 

  • Ichikawa Y, Ishikawa T, Momiyama N, Yamaguchi S, Masui H, Hasegawa S, Chishima T, Takimoto A, Kitamura H, Akitaya T, Hosokawa T, Mitsuhashi M, Shimada H. Detection of regional lymph node metastases in colon cancer by using RT-PCR for matrix metallo-proteinase-7, matrilysin. Clin Exp Metastasis 1998; 16: 3–8.

    Article  CAS  PubMed  Google Scholar 

  • Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening S. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 1997; 74: 220–223.

    Article  CAS  PubMed  Google Scholar 

  • Jung K, Laube C, Lein M, Türk I, Lichtinghagen R, Rudolph B, Schnorr D, Loening S. Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer. Int J Cancer 1998; 78: 392–393.

    Article  CAS  PubMed  Google Scholar 

  • Karameris A, Panagou P, Tsilalis T, Bouros D. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous cell lung carcinomas. Am J Respir Crit Care Med 1997; 156: 1930–1936.

    CAS  PubMed  Google Scholar 

  • Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB. Evidence that transforming growth factor-α is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417–428.

    Article  CAS  PubMed  Google Scholar 

  • McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000; 6: 149–156.

    Article  CAS  PubMed  Google Scholar 

  • MacDougall JR, Bani MR, Lin Y, Rak Y, Kerbel RS. The 92 kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cell. Cancer Res 1995; 55: 4174–4181.

    CAS  PubMed  Google Scholar 

  • Martinella-Catusse C, Nawrocki B, Gilles C, Birembaut P, Polette M. Matrix-metalloproteinases in bronchopulmonary carcinomas. Histol Histopathol 1999; 14: 839–843.

    CAS  PubMed  Google Scholar 

  • Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G, Chambon P, Basset P. Increased stromelysin-3 is associated with local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1993; 53: 165–169.

    CAS  PubMed  Google Scholar 

  • Murray GI, Duncan ME, O’Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-I is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 461–462.

    Article  CAS  PubMed  Google Scholar 

  • Murray GI, Duncan ME, O’Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-I is associated with poor prognosis in eosophageal cancer. J Pathol 1998; 185: 256–261.

    Article  CAS  PubMed  Google Scholar 

  • Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491–21494.

    Article  CAS  PubMed  Google Scholar 

  • Nawrocki B, Polette M, Marchand V, Monteau M, Gillery P, Tournier JM, Birembaut P. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morpohological analyses. Int J Cancer 1997; 72: 556–564.

    Article  CAS  PubMed  Google Scholar 

  • Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135–1149.

    CAS  PubMed  Google Scholar 

  • Newell KJ, Witty JP, Rodgers W, Matrisian LM. Expression and localization of matrix-degrading metalloproteinases during colorectal carcinogenesis. Mol Carcinog 1994; 10: 199–206.

    Article  CAS  PubMed  Google Scholar 

  • Noël A, Boulay A, Kebers F, Kannan R, Hajitou A, Calberg-Bacq CM, Basset P, Rio MC, Foidart JM. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 2000; 19: 1605–1612.

    Article  PubMed  Google Scholar 

  • Noël A, Polette M, Lewalle JM, Munaut C, Emonard H, Birembaut P, Foidart JM. Coordinate enhancement of gelatinase A mRNA and activity levels in human fibroblasts in response to breast adenocarcinoma cells. Int J Cancer 1994; 56: 331–336.

    Article  PubMed  Google Scholar 

  • Polette M, Clavel C, Cockett M, Girod de Bentzmann S, Murphy G, Birembaut P. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invas Metast 1993; 13: 31–37.

    CAS  Google Scholar 

  • Polette M, Gilles C, Marchand V, Seiki M, Tournier JM, Birembaut P. Induction of membrane-type matrix metalloproteinase (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells. Clin Exp Metastasis 1997; 15: 157–163.

    Article  CAS  PubMed  Google Scholar 

  • Remacle A, Noël A, Duggan C, McDermott E, O’Higgins N, Foidart JM, Duffy MJ. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 1998; 77: 926–931.

    Article  CAS  PubMed  Google Scholar 

  • Remacle A, McCarthy K, Noël A, Maguire T, McDermott E, O’Higgins N, Foidart JM, Duffy MJ. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000; 89: 118–121.

    Article  CAS  PubMed  Google Scholar 

  • Stearns MM, Stearns M. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res 1996; 8: 63–67.

    CAS  ADS  PubMed  Google Scholar 

  • Stetler-Stevenson WG, Bersch N, Golde DW. Tissue inhibitor of metalloproteinases-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett 1992; 296: 231–234.

    Article  CAS  PubMed  Google Scholar 

  • Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface ectivation of the 72 kD type IV collagenase: isolation of the activated form of the membrane metalloproteinase. J Biol Chem 1995; 270: 5331–5338.

    Article  CAS  PubMed  Google Scholar 

  • Tetu B, Brisson J, Lapointe H, Bernard P. Prognostic significance of stromelysin 3, gelatinase A and urokinase expression in breast cancer. Hum Pathol 1998; 29: 979–985.

    Article  CAS  PubMed  Google Scholar 

  • Vaisanen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996; 180: 283–289.

    Article  CAS  PubMed  Google Scholar 

  • Visscher DW, Hoyhtya M, Ottosem SK, Liang CM, Sarkar FH, Crissman JD, Fridman R. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 1994; 59: 339–344.

    Article  CAS  PubMed  Google Scholar 

  • Werb Z, Tremble PM, Behrendtsen D, Crowley E, Damsky CH. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 1989; 109: 877–889.

    Article  CAS  PubMed  Google Scholar 

  • Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, Arimura Y, Endo T, Hinoda Y, Hosokawa M, Imai K. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 1999; 59: 3313–3316.

    CAS  PubMed  Google Scholar 

  • Zucker S, Lysik RM, Zarrabi MH, Moll U. Mr 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993; 53: 140–146.

    CAS  PubMed  Google Scholar 

  • Zucker S, Lysik RM, Dimassimo BI, Zarrabi MH, Moll UM, Grimson R, Tickle SP, Docherty AJ. Plasma assay of gelatinase B/tissue inhibitor of metalloproteinase complexes in cancer. Cancer 1995; 76: 700–708.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. I.N.S.E.R.M. U. 514, I.F.R. 53, and Laboratoire Pol Bouin, C.H.U. of REIMS, France

    Béatrice Nawrocki-Raby, Christine Clavel, Myriam Polette & Philippe Birembaut

Authors
  1. Béatrice Nawrocki-Raby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Clavel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Myriam Polette
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philippe Birembaut
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Laboratoire de Biologie des Tumeurs et du Développement, Faculté de Médecine Université de Liège, Belgium

    Jean-Michel Foidart

  2. Department of Pathology & Laboratory Medicine, University of Pennsylvania, USA

    Ruth J. Muschel

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Kluwer Academic Publishers

About this chapter

Cite this chapter

Nawrocki-Raby, B., Clavel, C., Polette, M., Birembaut, P. (2002). Clinical Aspects of Matrix Metalloproteinases. In: Foidart, JM., Muschel, R.J. (eds) Proteases and Their Inhibitors in Cancer Metastasis. Cancer Metastasis — Biology and Treatment, vol 4. Springer, Dordrecht. https://doi.org/10.1007/1-4020-2008-2_10

Download citation

  • DOI: https://doi.org/10.1007/1-4020-2008-2_10

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-0923-5

  • Online ISBN: 978-1-4020-2008-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation